• 1
    The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273: 199208.
  • 2
    Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study, a prospective, observational study. Ann Intern Med 2001;135: 18.
  • 3
    Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336: 17691775.
  • 4
    Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133: 933941.
  • 5
    Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ 1988;297: 519522.
  • 6
    Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 1990;97: 10801086.
  • 7
    Falkeborn M, Persson I, Terent A, Adami HO, Lithell H, Bergstrom R. Hormone replacement therapy and the risk of stroke, follow-up of a population-based cohort in Sweden. Arch Intern Med 1993;153: 12011209.
  • 8
    Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC. Decreased risk of stroke among postmenopausal hormone users, results from a national cohort. Arch Intern Med 1993;153: 7379.
  • 9
    Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343: 522529.
  • 10
    Cherry N, Gilmour K, Hannaford P, et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2001;360: 20012008.
  • 11
    Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 4957.
  • 12
    Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001 ;103: 638642.
  • 13
    Hulley S, Furberg C, Connor BE, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288: 5866.
  • 14
    Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomised controlled trial. JAMA 2002;288: 24322440.
  • 15
    Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345: 12431249.
  • 16
    Smoller WS, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomised trial. JAMA 2003;289: 26732684.
  • 17
    Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523534.
  • 18
    Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomised controlled trial. JAMA 2002;288: 321333
  • 19
    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy, the Women's Health Initiative randomised controlled trial. JAMA 2004;291: 17011712.
  • 20
    Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise—was it inevitable? Climacteric 2002;5: 317325.
  • 21
    MacLennan A, Sturdee D. The end of WISDOM. Climacteric 2002;5: 313316.
  • 22
    Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynaecol 1979;54: 7479.
  • 23
    Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Control Clin Trials 1996;17: 112.
  • 24
    Sourander L, Rajala T, Raiha I, Makinen J, Erkkola R, Helenius H. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352: 19651969.
  • 25
    Wilson PW, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med 1985;313: 10381043.
  • 26
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease, ten-year follow-up from the nurses’ health study. N Engl J Med 1991;325: 756762.
  • 27
    Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335: 453461.
  • 28
    Humphrey LL, Takano LMA, Chan BKS. Post Menopausal Hormone Replacement Therapy and Cardiovascular Disease. Rockville, Mary-land: Agency for Healthcare Research and Quality, 2002.
  • 29
    Bath PM, Gray LJAssociation between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005;330: 342.
  • 30
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340: 18011811.
  • 31
    Nabulsi AA, Folsom AR, White A, et al. Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328: 10691075.
  • 32
    The ESHRE Capri Workshop Group. Hormones and cardiovascular diseases: oral contraceptives and hormonal replacement therapy: differential effects on coronary heart disease, deep venous thrombosis and stroke. Hum Reprod 1998;13: 23252333.
  • 33
    Aune B, Oian P, Omsjo I, Osterud B. Hormone replacement therapy reduces the reactivity of monocytes and platelets in whole blood—a beneficial effect on atherogenesis and thrombus formation? Am J Obstet Gynecol 1995;173: 18161820.
  • 34
    Estelles A, Cano A, Falco C, et al. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause-influence of hormone replacement therapy. Thromb Haemost 1999;81: 104110.
  • 35
    Murphy DD, Cole NB, Greenberger V, Segal M. Estradiol increases dendritic spine density by reducing GABA neurotransmission in hip-pocampal neurons. J Neurosci 1998;18: 25502559.
  • 36
    Cushman M, Legault C, Connor BE, et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 1999;100: 717722.
  • 37
    Hermite LM. Sex hormones and cardiovascular risk. Acta Cardiol 1991;46: 357372.
  • 38
    Connor BE, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265: 18611867.
  • 39
    Connor BE. Postmenopausal estrogen and prevention bias. Ann Intern Med 1991;115: 455456.
  • 40
    Grodstein F, Manson JE, Stampfer MJ, Willett WC. The discrepancy between observational studies and randomised trials of menopausal hormone therapy. Ann Intern Med 2004;140: 764765 [author's reply 5–6].
  • 41
    Folsom AR, Mink PJ, Sellers TA, Hong CP, Potter CD. Hormonal replacement therapy and morbidity and mortality in a prospective study of post menopausal women. Am J Public Health 1995;85: 11281132.
  • 42
    Cauley JA, Cummings SR, Black DM, Mascioli SR, Seeley DG. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990;163: 14381444.
  • 43
    Criqui MH, Suarez L, Connor BE, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128: 606614.
  • 44
    Grodstein F, Manson JE, Stampfer MJ. Postmenopausal hormone replacement therapy. Ann Intern Med 2003;138: 688 [author's reply 9].
  • 45
    Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002; 360: 942944.
  • 46
    Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288: 872881.
  • 47
    Salpeter JM, Walsh E, Greyber TM, Ormiston EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19: 791804.